510 related articles for article (PubMed ID: 23881169)
1. Erythropoietin is involved in the angiogenic potential of bone marrow macrophages in multiple myeloma.
De Luisi A; Binetti L; Ria R; Ruggieri S; Berardi S; Catacchio I; Racanelli V; Pavone V; Rossini B; Vacca A; Ribatti D
Angiogenesis; 2013 Oct; 16(4):963-73. PubMed ID: 23881169
[TBL] [Abstract][Full Text] [Related]
2. Rhu-Epo down-regulates pro-tumorigenic activity of cancer-associated fibroblasts in multiple myeloma.
Desantis V; Frassanito MA; Tamma R; Saltarella I; Di Marzo L; Lamanuzzi A; Solimando AG; Ruggieri S; Annese T; Nico B; Vacca A; Ribatti D
Ann Hematol; 2018 Jul; 97(7):1251-1258. PubMed ID: 29589107
[TBL] [Abstract][Full Text] [Related]
3. Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients.
Lamanuzzi A; Saltarella I; Ferrucci A; Ria R; Ruggieri S; Racanelli V; Rao L; Annese T; Nico B; Vacca A; Ribatti D
Oncotarget; 2016 Mar; 7(12):14510-21. PubMed ID: 26919105
[TBL] [Abstract][Full Text] [Related]
4. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Vacca A; Ribatti D; Presta M; Minischetti M; Iurlaro M; Ria R; Albini A; Bussolino F; Dammacco F
Blood; 1999 May; 93(9):3064-73. PubMed ID: 10216103
[TBL] [Abstract][Full Text] [Related]
5. The erythropoietin receptor and its expression in tumor cells and other tissues.
Farrell F; Lee A
Oncologist; 2004; 9 Suppl 5():18-30. PubMed ID: 15591419
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma.
Ribatti D; Vacca A; Nico B; Quondamatteo F; Ria R; Minischetti M; Marzullo A; Herken R; Roncali L; Dammacco F
Br J Cancer; 1999 Feb; 79(3-4):451-5. PubMed ID: 10027312
[TBL] [Abstract][Full Text] [Related]
7. The hypoxia inducible factor/erythropoietin (EPO)/EPO receptor pathway is disturbed in a rat model of chronic kidney disease related anemia.
Landau D; London L; Bandach I; Segev Y
PLoS One; 2018; 13(5):e0196684. PubMed ID: 29738538
[TBL] [Abstract][Full Text] [Related]
8. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
9. Erythropoietin (EPO)-receptor signaling induces cell death of primary myeloma cells in vitro.
Våtsveen TK; Sponaas AM; Tian E; Zhang Q; Misund K; Sundan A; Børset M; Waage A; Brede G
J Hematol Oncol; 2016 Aug; 9(1):75. PubMed ID: 27581518
[TBL] [Abstract][Full Text] [Related]
10. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
11. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
[TBL] [Abstract][Full Text] [Related]
12. Bone marrow angiogenic ability and expression of angiogenic cytokines in myeloma: evidence favoring loss of marrow angiogenesis inhibitory activity with disease progression.
Kumar S; Witzig TE; Timm M; Haug J; Wellik L; Kimlinger TK; Greipp PR; Rajkumar SV
Blood; 2004 Aug; 104(4):1159-65. PubMed ID: 15130943
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin is involved in growth and angiogenesis in malignant tumours of female reproductive organs.
Yasuda Y; Fujita Y; Masuda S; Musha T; Ueda K; Tanaka H; Fujita H; Matsuo T; Nagao M; Sasaki R; Nakamura Y
Carcinogenesis; 2002 Nov; 23(11):1797-805. PubMed ID: 12419827
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin priming improves the vasculogenic potential of G-CSF mobilized human peripheral blood mononuclear cells.
Kang J; Yun JY; Hur J; Kang JA; Choi JI; Ko SB; Lee J; Kim JY; Hwang IC; Park YB; Kim HS
Cardiovasc Res; 2014 Oct; 104(1):171-82. PubMed ID: 25082847
[TBL] [Abstract][Full Text] [Related]
15. Human erythropoietin increases the pro-angiogenic potential of A2780 ovarian adenocarcinoma cells under hypoxic conditions.
Kriška J; Solár P; Varinská L; Solárová Z; Kimáková P; Mojžiš J; Fedoročko P; Sytkowski AJ
Oncol Rep; 2013 Sep; 30(3):1455-62. PubMed ID: 23807540
[TBL] [Abstract][Full Text] [Related]
16. β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase.
Su KH; Shyue SK; Kou YR; Ching LC; Chiang AN; Yu YB; Chen CY; Pan CC; Lee TS
J Cell Physiol; 2011 Dec; 226(12):3330-9. PubMed ID: 21321940
[TBL] [Abstract][Full Text] [Related]
17. Src transduces erythropoietin-induced differentiation signals through phosphatidylinositol 3-kinase.
Kubota Y; Tanaka T; Kitanaka A; Ohnishi H; Okutani Y; Waki M; Ishida T; Kamano H
EMBO J; 2001 Oct; 20(20):5666-77. PubMed ID: 11598010
[TBL] [Abstract][Full Text] [Related]
18. In vivo angiogenic activity of erythropoietin.
Ribatti D
Methods Mol Biol; 2013; 982():227-35. PubMed ID: 23456873
[TBL] [Abstract][Full Text] [Related]
19. Does erythropoietin have a dark side? Epo signaling and cancer cells.
Sytkowski AJ
Sci STKE; 2007 Jul; 2007(395):pe38. PubMed ID: 17636183
[TBL] [Abstract][Full Text] [Related]
20. Pigment epithelium-derived factor inhibits erythropoietin-induced retinal endothelial cell angiogenesis by suppression of PI3K/Akt pathway.
Haribalaganesh R; Sheikpranbabu S; Banumathi E; Gurunathan S
Exp Eye Res; 2010 Jun; 90(6):726-33. PubMed ID: 20298690
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
